REPL250117P2500
- 0.00
- 0.000.00%
Replimune Newsroom
Replimune Group Is Maintained at Outperform by BMO Capital
H.C. Wainwright Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $21
Replimune Group Analyst Ratings
HC Wainwright & Co. Maintains Buy on Replimune Group, Raises Price Target to $21
Barclays Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $17
Barclays Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $17
BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $27
Barclays Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $17
BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $18
Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Replimune Group (REPL)
Jefferies Maintains Buy on Replimune Group, Raises Price Target to $19
Replimune Group Analyst Ratings
BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $18
Replimune Group Analyst Ratings
H.C. Wainwright Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $17
J.P. Morgan Maintains Replimune(REPL.US) With Buy Rating, Cuts Target Price to $16
BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $14
Barclays Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $17
H.C. Wainwright Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $17
Replimune Group Analyst Ratings